- Home
- EIC vs IPSC Comparison
EIC vs IPSC Comparison
Compare EIC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIC | IPSC |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.7M | 189.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EIC | IPSC |
|---|---|---|
| Price | $9.75 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.00 | $3.50 |
| AVG Volume (30 Days) | 182.6K | ★ 896.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 14.01% | N/A |
| EPS Growth | N/A | ★ 29.07 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $6,589,000.00 |
| Revenue This Year | $9.27 | $1,590.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $9.08 | $23.14 |
| Revenue Growth | N/A | ★ 194.81 |
| 52 Week Low | $9.44 | $0.34 |
| 52 Week High | $15.89 | $2.71 |
Technical Indicators
Market Signals| Indicator | EIC | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 69.16 |
| Support Level | N/A | $0.49 |
| Resistance Level | $11.34 | N/A |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 45.56 | 80.50 |
Price Performance
Historical ComparisonAbout EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.